TrialNature cancer2025
Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial.
Aurelien Marabelle et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
27 papers cite it
this paperpooled itcites it